{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:08:00Z","timestamp":1791824880020,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"DOI":"10.1186\/s12941-025-00785-9","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T13:51:51Z","timestamp":1742392311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["TROJAN-MDR: in vitro activity of cefiderocol and comparators against multidrug-resistant Enterobacterales and Pseudomonas aeruginosa strains in Southern France, evaluation of available testing methods performances"],"prefix":"10.1186","volume":"24","author":[{"given":"Massinissa","family":"Benyahia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Magnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jean-Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romaric","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Boutet-Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Marchandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Genieyz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madjid","family":"Morsli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Lavigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"785_CR1","unstructured":"WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024."},{"key":"785_CR2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/cid\/cix411","volume":"65","author":"JI Barrasa-Villar","year":"2017","unstructured":"JI Barrasa-Villar C Aibar-Rem\u00f3n P Prieto-Andr\u00e9s R Mareca-Do\u00f1ate J Moliner-Lahoz 2017 Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms Clin Infect Dis 65 644 652","journal-title":"Clin Infect Dis"},{"key":"785_CR3","doi-asserted-by":"crossref","unstructured":"R Cant\u00f3n P Ruiz-Garbajosa 2023 Treatment guidelines for multidrug-resistant Gram-negative microorganisms Rev Espanola Quimioter 36 Suppl 1 46 51","DOI":"10.37201\/req\/s01.11.2023"},{"key":"785_CR4","doi-asserted-by":"crossref","unstructured":"S Karakonstantis M Rousaki EI Kritsotakis 2022 Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance Antibiotics 11 723","DOI":"10.3390\/antibiotics11060723"},{"key":"785_CR5","doi-asserted-by":"crossref","first-page":"e00951","DOI":"10.1128\/JCM.00951-20","volume":"59","author":"PJ Simner","year":"2020","unstructured":"PJ Simner R Patel 2020 Cefiderocol antimicrobial susceptibility testing considerations: the Achilles\u2019 heel of the Trojan horse? J Clin Microbiol 59 e00951 e1020","journal-title":"J Clin Microbiol"},{"key":"785_CR6","unstructured":"EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Available online: https:\/\/www.eucast.org\/. Accessed 21 Oct 2024."},{"key":"785_CR7","unstructured":"Clinical & Laboratory Standards Institute: CLSI Guidelines. Available online: https:\/\/clsi.org\/. Accessed 21 Oct 2024."},{"key":"785_CR8","doi-asserted-by":"crossref","first-page":"1156.e1","DOI":"10.1016\/j.cmi.2022.04.013","volume":"28","author":"RA Bonnin","year":"2022","unstructured":"RA Bonnin C Emeraud AB Jousset T Naas L Dortet 2022 Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant Enterobacterales Clin Microbiol Infect 28 1156.e1 1156.e5","journal-title":"Clin Microbiol Infect"},{"key":"785_CR9","doi-asserted-by":"crossref","first-page":"652.e1","DOI":"10.1016\/j.cmi.2022.12.021","volume":"29","author":"L Devoos","year":"2023","unstructured":"L Devoos A Biguenet J Rousselot M Bour P Pl\u00e9siat D Fournier  2023 Performance of discs, Sensititre EUMDROXF microplates and MTS gradient strips for the determination of the susceptibility of multidrug-resistant Pseudomonas aeruginosa to cefiderocol Clin Microbiol Infect 29 652.e1 652.e8","journal-title":"Clin Microbiol Infect"},{"key":"785_CR10","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/jac\/dkad134","volume":"78","author":"C Emeraud","year":"2023","unstructured":"C Emeraud C Gonzalez L Dortet 2023 Comparison of ComASP\u00ae and UMIC\u00ae methods with the reference method for cefiderocol susceptibility testing on carbapenem-resistant Enterobacterales J Antimicrob Chemother 78 1800 1801","journal-title":"J Antimicrob Chemother"},{"key":"785_CR11","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/jac\/dkad149","volume":"78","author":"L Dortet","year":"2023","unstructured":"L Dortet C Niccolai N Pfennigwerth S Frisch C Gonzalez A Antonelli  2023 Performance evaluation of the UMIC\u00ae Cefiderocol to determine MIC in Gram-negative bacteria J Antimicrob Chemother 78 1672 1676","journal-title":"J Antimicrob Chemother"},{"key":"785_CR12","unstructured":"Centre National de R\u00e9f\u00e9rence de la R\u00e9sistance aux Antibiotiques. Available online: https:\/\/www.cnr-resistance-antibiotiques.fr\/. Accessed 21 Oct 2024."},{"key":"785_CR13","unstructured":"EUCAST. Clinical breakpoints and dosing of antibiotics. Available online: https:\/\/www.eucast.org\/clinical_breakpoints. Accessed 21 Oct 2024."},{"key":"785_CR14","unstructured":"ISO. EN ISO 20776-2:2007\u2014Clinical laboratory testing and in vitro diagnostic test systems\u2014Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices\u2014Part 2: Evaluation of performance of antimicrobial susceptibility test devices (ISO 20776-2:2007). ITeh Standards. Available online: https:\/\/standards.iteh.ai\/catalog\/standards\/cen\/e58114a5-4af0-488d-addf-f410a8445ee0\/en-iso-20776-2-2007. Accessed 21 Oct 2024."},{"key":"785_CR15","unstructured":"ISO. EN ISO 20776-2:2021\u2014Clinical laboratory testing and invitro diagnostic test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices\u2014Part 2: Evaluation of performance of antimicrobial susceptibility test devices against reference broth micro-dilution (ISO 20776-2:2021). ITeh Standards. Available online: https:\/\/standards.iteh.ai\/catalog\/standards\/cen\/92fc193a-5135-4d74-b3b5-a6962a16e505\/en-iso-20776-2-2022. Accessed 21 Oct 2024."},{"key":"785_CR16","doi-asserted-by":"crossref","unstructured":"D Shortridge JM Streit R Mendes M Castanheira 2020 In vitro activity of cefiderocol against U.S. and European Gram-negative clinical isolates collected in 2020 as part of the SENTRY antimicrobial surveillance program Microbiol Spectr 2022 10 e0271221","DOI":"10.1128\/spectrum.02712-21"},{"key":"785_CR17","doi-asserted-by":"crossref","unstructured":"JA Karlowsky MA Hackel M Takemura Y Yamano R Echols DF Sahm 2022 In vitro susceptibility of Gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019 Antimicrob Agents Chemother 66 e0199021","DOI":"10.1128\/AAC.01990-21"},{"key":"785_CR18","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3390\/antibiotics11101352","volume":"11","author":"S Oueslati","year":"2022","unstructured":"S Oueslati P Bogaerts L Dortet S Bernabeu H Ben Lakhal C Longshaw  2022 In vitro activity of cefiderocol and comparators against carbapenem-resistant Gram-negative pathogens from France and Belgium Antibiotics 11 1352","journal-title":"Antibiotics"},{"key":"785_CR19","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/jac\/dkaa117","volume":"75","author":"M Delgado-Valverde","year":"2020","unstructured":"M Delgado-Valverde MDC Conejo L Serrano F Fern\u00e1ndez-Cuenca \u00c1 Pascual 2020 Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia J Antimicrob Chemother 75 1840 1849","journal-title":"J Antimicrob Chemother"},{"key":"785_CR20","doi-asserted-by":"crossref","unstructured":"L Malisova I Vrbova K Pomorska V Jakubu H Zemlickova 2023 In vitro activity of cefiderocol against carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa Microb Drug Resist 29 10 485 491","DOI":"10.1089\/mdr.2023.0090"},{"key":"785_CR21","doi-asserted-by":"crossref","unstructured":"A Santerre Henriksen F Arena M Attwood R Canton S Gatermann T Naas  2024 In vitro activity of cefiderocol against european Enterobacterales, including isolates resistant to meropenem and recent \u03b2-lactam\/\u03b2-lactamase inhibitor combinations Microbiol Spectr. 2024 e0418123","DOI":"10.1128\/spectrum.04181-23"},{"key":"785_CR22","doi-asserted-by":"crossref","unstructured":"A Santerre Henriksen K Jeannot A Oliver JD Perry MW Pletz S Stefani  2024 In vitro activity of cefiderocol against european Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent \u03b2-lactam\/\u03b2-lactamase inhibitor combinations Microbiol Spectr. 12 e0383623","DOI":"10.1128\/spectrum.03836-23"},{"key":"785_CR23","doi-asserted-by":"crossref","unstructured":"S Mushtaq Z Sadouki A Vickers DM Livermore N Woodford 2020 In vitro activity of cefiderocol, a siderophore cephalosporin, against multidrug-resistant Gram-negative bacteria Antimicrob Agents Chemother 64 e01582 e1620","DOI":"10.1128\/AAC.01582-20"},{"key":"785_CR24","doi-asserted-by":"crossref","unstructured":"C Longshaw D Manissero M Tsuji R Echols Y Yamano 2020 In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe JAC Antimicrob Resist. 2 dlaa060","DOI":"10.1093\/jacamr\/dlaa060"},{"key":"785_CR25","doi-asserted-by":"crossref","unstructured":"MG Wise JA Karlowsky MA Hackel M Takemura Y Yamano R Echols  2023 In vitro activity of cefiderocol against meropenem-nonsusceptible Gram-negative bacilli with defined \u03b2-Lactamase carriage: SIDERO-WT surveillance studies, 2014\u20132019 Microb Drug Resist 29 360 370","DOI":"10.1089\/mdr.2022.0279"},{"key":"785_CR26","doi-asserted-by":"crossref","unstructured":"A Ito T Sato M Ota M Takemura T Nishikawa S Toba  2018 In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria Antimicrob Agents Chemother 62 e01454 e1517","DOI":"10.1128\/AAC.01454-17"},{"key":"785_CR27","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jgar.2020.07.009","volume":"22","author":"N Kohira","year":"2020","unstructured":"N Kohira MA Hackel Y Ishioka M Kuroiwa DF Sahm T Sato  2020 Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014) J Glob Antimicrob Resist 22 738 741","journal-title":"J Glob Antimicrob Resist"},{"key":"785_CR28","doi-asserted-by":"crossref","first-page":"ifad276","DOI":"10.1093\/ofid\/ofad276","volume":"10","author":"PJ Simner","year":"2023","unstructured":"PJ Simner Y Bergman R Conzemius E Jacobs T Tekle S Beisken  2023 An NDM-producing Escherichia coli clinical isolate exhibiting resistance to cefiderocol and the combination of ceftazidime-avibactam and aztreonam: another step toward pan-\u03b2-lactam resistance Open Forum Infect Dis 10 ifad276","journal-title":"Open Forum Infect Dis"},{"key":"785_CR29","doi-asserted-by":"crossref","unstructured":"M Delgado-Valverde I Portillo-Calder\u00f3n E Recacha P P\u00e9rez-Palacios A Pascual 2023 In vitro activity of cefiderocol compared to other antimicrobials against a collection of metallo-beta-lactamase-producing Gram-negative bacilli from southern Spain Microbiol Spectr 11 e0493622","DOI":"10.1128\/spectrum.04936-22"},{"key":"785_CR30","first-page":"e00102","volume":"33","author":"JDD Pitout","year":"2019","unstructured":"JDD Pitout G Peirano MM Kock K-A Strydom Y Matsumura 2019 The global ascendency of OXA-48-type carbapenemases Clin Microbiol Rev 33 e00102 e119","journal-title":"Clin Microbiol Rev"},{"key":"785_CR31","volume":"66","author":"SE Boyd","year":"2022","unstructured":"SE Boyd A Holmes R Peck DM Livermore W Hope 2022 OXA-48-like \u03b2-lactamases: global epidemiology, treatment options, and development pipeline Antimicrob Agents Chemother 66 e0021622","journal-title":"Antimicrob Agents Chemother"},{"key":"785_CR32","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00024-19","volume":"4","author":"C Fr\u00f6hlich","year":"2019","unstructured":"C Fr\u00f6hlich V S\u00f8rum AM Thomassen PJ Johnsen H-KS Leiros \u00d8 Samuelsen 2019 OXA-48-mediated ceftazidime-avibactam resistance is associated with evolutionary trade-offs mSphere. 4 e0002419","journal-title":"mSphere."},{"key":"785_CR33","volume":"66","author":"L Poirel","year":"2022","unstructured":"L Poirel J-M Ortiz de la Rosa M Sadek P Nordmann 2022 Impact of acquired broad-spectrum \u03b2-lactamases on susceptibility to cefiderocol and newly developed \u03b2-lactam\/\u03b2-lactamase inhibitor combinations in Escherichia coli and Pseudomonas aeruginosa Antimicrob Agents Chemother 66 e0003922","journal-title":"Antimicrob Agents Chemother"},{"key":"785_CR34","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ijantimicag.2018.11.005","volume":"52","author":"L Poirel","year":"2018","unstructured":"L Poirel N Kieffer P Nordmann 2018 Stability of cefiderocol against clinically significant broad-spectrum oxacillinases Int J Antimicrob Agents 52 866 867","journal-title":"Int J Antimicrob Agents"},{"key":"785_CR35","doi-asserted-by":"crossref","unstructured":"S Vasoo SA Cunningham NC Cole PC Kohner SR Menon KM Krause  2015 In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing Gram-negative bacilli Antimicrob Agents Chemother 59 7842 7846","DOI":"10.1128\/AAC.02019-15"},{"key":"785_CR36","doi-asserted-by":"crossref","unstructured":"Y-S Huang P-Y Chen P-C Chou J-T Wang 2023 In vitro activities and inoculum effects of cefiderocol and aztreonam-avibactam against metallo-\u03b2-lactamase-producing Enterobacteriaceae Microbiol Spectr 11 e0056923","DOI":"10.1128\/spectrum.00569-23"},{"key":"785_CR37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/jac\/dkaa344","volume":"76","author":"CM Gill","year":"2021","unstructured":"CM Gill TE Asempa DP Nicolau 2021 Efficacy of human-simulated exposures of meropenem\/vaborbactam and meropenem against OXA-48 \u03b2-lactamase-producing Enterobacterales in the neutropenic murine thigh infection model J Antimicrob Chemother 76 184 188","journal-title":"J Antimicrob Chemother"},{"key":"785_CR38","doi-asserted-by":"crossref","unstructured":"R Larcher P Laffont-Lozes C Roger R Doncesco C Groul-Viaud A Martin  2022 Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-beta-lactamase producing Enterobacterales and other difficult-to-treat resistance in Gram-negative bacteria: a real-life study Front Cell Infect Microbiol 12 1048633","DOI":"10.3389\/fcimb.2022.1048633"},{"key":"785_CR39","doi-asserted-by":"crossref","unstructured":"Horcajada JP, Montero M, Oliver A, Sorl\u00ed L, Luque S, G\u00f3mez-Zorrilla S, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32.","DOI":"10.1128\/CMR.00031-19"},{"key":"785_CR40","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jiph.2022.12.015","volume":"16","author":"P Lumbreras-Iglesias","year":"2023","unstructured":"P Lumbreras-Iglesias M Toro de X V\u00e1zquez E Garc\u00eda-Car\u00fas MR Rodicio J Fern\u00e1ndez 2023 High-risk international clones ST66, ST171 and ST78 of Enterobacter cloacae complex causing blood stream infections in Spain and carrying blaOXA-48 with or without mcr-9 J Infect Public Health 16 272 279","journal-title":"J Infect Public Health"},{"key":"785_CR41","doi-asserted-by":"crossref","first-page":"e04144","DOI":"10.1128\/spectrum.04144-22","volume":"11","author":"D Nobrega","year":"2023","unstructured":"D Nobrega G Peirano Y Matsumura JDD Pitout 2023 Molecular epidemiology of global carbapenemase-producing Citrobacter spp. (2015\u20132017) Microbiol Spectr. 11 e04144 e4222","journal-title":"Microbiol Spectr."},{"key":"785_CR42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12941-024-00731-1","volume":"23","author":"V Jean-Pierre","year":"2024","unstructured":"V Jean-Pierre P Sorlin K Jeannot R Chiron J-P Lavigne A Pantel  2024 Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus Ann Clin Microbiol Antimicrob 23 78","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"785_CR43","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/jac\/dkac080","volume":"77","author":"E Matuschek","year":"2022","unstructured":"E Matuschek C Longshaw M Takemura Y Yamano G Kahlmeter 2022 Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing J Antimicrob Chemother 77 1662 1669","journal-title":"J Antimicrob Chemother"},{"key":"785_CR44","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3390\/antibiotics12030604","volume":"12","author":"G Bianco","year":"2023","unstructured":"G Bianco M Boattini S Comini G Banche R Cavallo C Costa 2023 Disc diffusion and ComASP\u00ae cefiderocol microdilution panel to overcome the challenge of cefiderocol susceptibility testing in clinical laboratory routine Antibiotics 12 604","journal-title":"Antibiotics"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00785-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-025-00785-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00785-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T13:52:45Z","timestamp":1742392365000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-025-00785-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1186\/s12941-025-00785-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5326846\/v1","asserted-by":"object"}]},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This research was partially supported by SHIONOGI & Co. which provided supplies for antimicrobial susceptibility testing (disk, medium and commercial BMD assays) and for open access fees. AP received fees as Advisory Board member from SHIONOGI & Co., Ltd., Osaka, Japan.  However, the funder did not influence the study design, data collection and analysis, decision to publish, or the preparation of the manuscript in any way.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}